Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neuromodulation and Cognitive Training for Substance Use Disorders

NCT: NCT04426214 · TERMINATED

NCT IDNCT04426214
StatusTERMINATED
Start Date2021-07-16
Completion2026-06-20
SponsorUniversity of Minnesota (OTHER)
First posted
Last updated

Brief Summary

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.

Frequently Asked Questions

What is Neuromodulation and Cognitive Training for Substance Use Disorders?

Neuromodulation and Cognitive Training for Substance Use Disorders is a clinical trial registered under NCT04426214. Current status: TERMINATED.

What is the status of NCT04426214?

The current status of NCT04426214 (Neuromodulation and Cognitive Training for Substance Use Disorders) is: TERMINATED.

When did Neuromodulation and Cognitive Training for Substance Use Disorders start?

Neuromodulation and Cognitive Training for Substance Use Disorders started on 2021-07-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.